Overview
Swiss online pharmacy's 2025 external revenue grew 11.1%, achieving growth targets
2025 revenue increased by as much as 12.4% to CHF 1.12 billion, achieving growth targets
Digital services, including TeleClinic, saw significant growth in 2025
Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicines
Outlook
DocMorris confirms EBITDA breakeven in 2026 and free cash flow breakeven in 2027
Company specifies 2025 EBITDA forecast to a range of minus CHF 48 to minus CHF 52 million
Result Drivers
DIGITAL SERVICES GROWTH - TeleClinic revenue increased by 124% in 2025, highlighting its strategic importance in the German market
AI ASSISTANT USAGE - Introduction of AI health assistant saw usage by every third app user, enhancing digital platform expansion
Q4 REVENUE ACCELERATION - Q4 external revenue rose 15.5%, driven by increased marketing efficiency for prescription medicines
Key Details
Metric
FY External Revenue
Beat/Miss
Actual
CHF 1.19 bln
Consensus Estimate
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for DocMorris AG is CHF8.10, about 25.5% above its January 19 closing price of CHF6.46
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .